Ventrus Biosciences Inc. (VTUS -9.8%) slides after getting FDA feedback requiring a second Phase 3 study of its diltiazem hydrochloride cream - a treatment for anal fissures - before any new drug application can be filed. The drug developer says it expects to file the NDA following completion of the second Phase 3 study, with results expected early Q4 2013, and expects to file an NDA late in Q4 2013 with an anticipated PDUFA date near the end of 2014.
Ventrus Biosciences Inc. (VTUS -9.8%) slides after getting FDA feedback requiring a second Phase...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs